1.Wong, DT, Bymaster, FP, Engleman, EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57:411–441.
2.Beasley, CM Jr, Holman, SL, Potvin, JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry. 1993;5:199–207.
3.Cookson, J. Side-effects of antidepressants. Br J Psychiatry Suppl. 1993;(20):20–24.
4.Burrows, GD, Maguire, KP, Norman, TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 1998;59(Suppl 14):4–7.
5.Nelson, JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry. 1999;46:1301–1308.
6.Poston, WS, Foreyt, JP. Sibutramine and the management of obesity. Expert Opin Pharmacother. 2004;5:633–642.
7.Millan, MJ, Lejeune, F, Gobert, A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol. 2000;14:114–138.
8.Owens, MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;65(Suppl 4):5–10.
9.Benveniste, H, Huttemeier, PC. Microdialysis—theory and application. Prog Neurobiol. 1990;35:195–215.
10.Bymaster, FP, Katner, JS, Nelson, DL, et al.Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699–711.
11.Bymaster, FP, Zhang, W, Carter, PA, et al.Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002;160:353–361.
12.Wong, DT, Bymaster, FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drag Res. 2002;58:169–222.
13.Invemizzi, RW, Garattini, S. Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:819–827.
14.Wikell, C, Bergqvist, PB, Hjorth, S, Apelqvist, G, Bjork, H, Bengtsson, F. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy. Clin Neuropharmacol. 1998;21:296–306.
15.Dawson, LA, Nguyen, HQ, Geiger, A. Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology. 1999;38:1153–1163.
16.Koch, S, Hemrick-Luecke, SK, Thompson, LK, et al.Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45:935–944.
17.Vaishnavi, SN, Nemeroff, CB, Plott, SJ, et al.Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55:320–322.
18.Millan, MJ, Gobert, A, Lejeune, F, et al.S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther. 2001;298:565–580.
19.Weikop, P, Kehr, J, Scheel-Kruger, J. The role of alphal- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J Psychopharmacol. 2004;18:395–403.
20.Piacentini, MF, Clinckers, R, Meeusen, R, Sarre, S, Ebinger, G, Michotte, Y. Effects of venlafaxine on extracellular 5-HT, dopamine and noradrenaline in the hippocampus and on peripheral hormone concentrations in the rat in vivo. Life Sci. 2003;73:2433–2442.
21.Moret, C, Marien, M. Effects of venlafaxine on extracellular levels of 5-HT and noradrenaline in guinea pig hypothalamus. Society for Neuroscience Abstracts. 1997;23:1225. Abstract 485.5.
22.David, DJ, Bourin, M, Jego, G, Przybylski, C, Jolliet, P, Gardier, AM. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol. 2003;140:1128–1136.
23.Mochizuki, D, Tsujita, R, Yamada, S, et al.Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl). 2002;162:323–332.
24.Moret, C, Briley, M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem. 1997;69:815–822.
25.Kihara, T, Ikeda, M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther. 1995;272:177–183.
26.Gobert, A, Rivet, JM, Cistarelli, JM, Millan, MJ. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem. 1997;68:1326–1329.
27.Engleman, EA, Perry, KW, Mayle, DA, Wong, DT. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 1995;12:287–295.
28.Gur, E, Dremencov, E, Lerer, B, Newman, ME. Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur J Pharmacol. 1999;372:17–24.
29.Bel, N, Artigas, F. Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology. 1999;21:745–754.
30.Felton, TM, Kang, TB, Hjorth, S, Auerbach, SB. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:297–305.
31.Harvey, AT, Rudolph, RL, Preskorn, SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503–509.
32.Chalon, SA, Granier, LA, Vandenhende, FR, et al.Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28:1685–1693.
33.Palmier, C, Puozzo, C, Lenehan, T, et al.Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant, milnacipran. Eur J Clin Pharmacol. 1998;37:235–238.
34.Turcotte, JE, Debonnel, G, de Montigny, C, Hebert, C, Blier, P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511–521.
35.Vincent, S, Bieck, PR, Garland, EM, et al.Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004;109:3202–3207.
36.Abdelmawla, AH, Langley, RW, Szabadi, E, et al.Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol. 1999;48:345–354.
37.Puozzo, C, Leonard, BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol. 1996;11(Suppl 4):15–27.
38.Troy, SM, Parker, VP, Hicks, DR, Pollack, GM, Chiang, ST. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. J Clin Pharmacol. 1997;37:954–961.
39.Lantz, RJ, Gillespie, TA, Rash, TJ, et al.Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142–1150.
40.Otton, SV, Ball, SE, Cheung, SW, Inaba, T, Rudolph, RL, Sellers, EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41:149–156.
41.Sawada, Y, Ohtani, H. Pharmacokinetics and drug interactions of antidepressive agents [Japanese]. Nippon Rinsho. 2001;59:1539–1545.
42.Perahia, D, Pritchett, YL, Lee, TC, Tran, PF. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Available at: http://www.nimh.nih.gov/ncdeu/2005abstracts.pdf. Abstracts of NCDEU 2005; Poster 1-14.
43.Lopez-Ibor, J, Guelfi, JD, Pletan, Y, Toumoux, A, Prost, JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol. 1996;11(Suppl 4):41–46.
44.Puech, A, Montgomery, SA, Prost, JF, Solles, A, Briley, M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997;12:99–108.
45.Thase, ME, Entsuah, AR, Rudolph, RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.
46.Stahl, SM, Entsuah, R, Rudolph, RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002;52:1166–1174.
47.Goldstein, DJ, Lu, Y, Detke, MJ, Wiltse, C, Mallinckrodt, C, Demitrack, MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389–399.
48.Anderson, IM. Meta-analytical studies on new antidepressants. Br Med Bull. 2001;57:161–178.
49.Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl). 1986;90:131–138.
50.Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord. 1990;18:289–299.
51.Anderson, IM, Tomenson, BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994;8:238–249.
52.Nelson, JC, Mazure, CM, Jatlow, PI, Bowers, MB Jr, Price, LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a doubleblind, randomized study. Biol Psychiatry. 2004;55:296–300.
53.Smith, D, Dempster, C, Glanville, J, Freemantle, N, Anderson, I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396–404.
54.Holliday, SM, Benfield, P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49:280–294.
55.Preskom, SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry. 1994;55(Suppl A):6–22.
56.Clerc, GE, Ruimy, P, Verdeau-Palles, J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9:139–143.
57.Dierick, M, Ravizza, L, Realini, R, Martin, A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:57–71.
58.Entsuah, AR, Huang, H, Thase, ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869–877.
59.Nemeroff, CB, Entsuah, R, Willard, LB, et al. Comprehensive pooled analysis of remission data: venlafaxine vs. SSRIs (COMPARE). Poster presented at: Annual Meeting of the American Psychiatric Association. May 17-22, 2003; San Francisco, Calif.
60.SirD'Souza, R, George, T, et al. Comparative efficacy of sertraline and venlafaxine XR in major depression. Poster presented at: Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
61.Owens, MJ, Knight, DL, Nemeroff, CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345–350.
62.Bielski, RJ, Ventura, D, Chang, CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65:1190–1196.
63.Montgomery, SA, Huusom, AK, Bothmer, J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50:57–64.
65.Clerc, G, Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol. 2001;16:145–151.
64.Sechter, D, Vandel, P, Weiller, E, et al.A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord. 2004;83:233–236.
66.Montes, JM, Ferrando, L, Saiz-Ruiz, J. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study. J Affect Disord. 2004;79:229–234.
67.Detke, MJ, Wiltse, CG, Mallinckrodt, CH, et al.Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14:457–470.
68.Thase, ME, Lu, Y, Joliat, MJ, et al. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Poster presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif.
70.Kessler, RC, McGonagle, KA, Zhao, S, et al.Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19.
71.Silverstone, PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry. 2004;65(Suppl 17):19–28.
72.Tanaka, M, Yoshida, M, Emoto, H, Ishii, H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol. 2000;405:397–406.
73.Ressler, KJ, Nemeroff, CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12(Suppl 1):2–19.
74.Iny, LJ, Pecknold, J, Suranyi-Cadotte, BE, et al.Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry. 1994;36:281–291.
75.Gorman, JM. Treatment of generalized anxiety disorder. J Clin Psychiatry. 2002;63(Suppl 8):17–23.
76.Pollack, MH, Zaninelli, R, Goddard, A, et al.Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:350–357
77.Rocca, P, Fonzo, V, Scotta, M, Zanalda, E, Ravizza, L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95:444–450.
78.Feldman, S, Weidenfeld, J. The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. Brain Res Bull. 1998;45:389–393.
79.Sevy, S, Papadimitriou, GN, Surmont, DW, Goldman, S, Mendlewicz, J. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry. 1989;25:141–152.
80.Rickels, K, Pollack, MH, Sheehan, DV, Haskins, JT. Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968–974.
81.Gelenberg, AJ, Lydiard, RB, Rudolph, RL, Aguiar, L, Haskins, JT, Salinas, E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283:3082–3088.
82.Davidson, JR, DuPont, RL, Hedges, D, et al.Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528–535.
83.Hackett, D, Haudiquet, V, Salinas, E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry. 2003;18:182–187.
84.Allgulander, C, Hackett, D, Salinas, E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15–22.
85.Allgulander, C, Mangano, R, Zhang, J, et al.Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19:387–396.
86.Rickels, K, Mangano, R, Khan, A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:488–496.
87.Liebowitz, MR, Mangano, RM, Bradwejn, J, Asnis, G; SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005;66:238–247.
88.Liebowitz, MR, Gelenberg, AJ, Munjack, D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190–198.
89.Whitaker, T, Bradwejn, J, Emilien, G, et al. Treatment of panic disorder with venlafaxine XR. Poster presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 7-11, 2003; San Juan, PR.
90.Pollack, MH, Emilien, G, Tzanis, E, et al. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the World Federation for the Society of Biological Psychiatry; February 6-13, 2004; Sydney, Australia.
91.Liebowitz, MR, Asnis, G, Tzanis, E, et al. A placebo-controlled trial of venlafaxine XR in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France.
92.Davidson, J, Lipschitz, A, Musgnung, J. A double-blind comparison of venlafaxine XR, sertraline, and placebo in the treatment of PTSD. Poster presented at: Annual meeting of the New Clinical Drug Evaluation Unit; June 1-4, 2004; Phoenix, Ariz.
93.Denys, D, van der Wee, N, van Megen, HJ, Westenberg, HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23:568–575.
94.Davidson, JR, Meoni, P, Haudiquet, V, Cantillon, M, Hackett, D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:4–13.
95.Tsukamoto, T, Kondoh, R, Ichikawa, K. Efficacy and safety of milnacipran in the treatment of generalized anxiety disorder: an open study. Int J Psychiatry Clin Pract. 2004;8:255–258
96.Dunner, DL, Goldstein, DJ, Mallinckrodt, C, Lu, Y, Detke, MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18:53–61.
97.Stahl, SM. Does depression hurt? J Clin Psychiatry. 2002;63:273–274.
98.Briley, M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs. 2003;4:42–45.
99.Briley, M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol. 2004(19 Suppl 1):S21–S25.
100.Delgado, PL. Common pathways of depression and pain. J Clin Psychiatry. 2004;65 (Suppl 12):16–19.
101.Fishbain, DA, Cutler, R, Rosomoff, HL, Rosomoff, RS. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med. 2000;1:310–316.
102.Entsuah, AR. Venlafaxine vs SSRIs: comparison of somatic symptom resolution. World J Biol Psychiatry. 2004;5(Suppl 1):92–97.
103.Max, MB, Lynch, SA, Muir, J, Shoaf, SE, Smoller, B, Dubner, R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250–1256.
104.Max, MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol. 1994;35(Suppl):S50–S53.
105.Staiger, TO, Gaster, B, Sullivan, MD, Deyo, RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003;28:2540–2545.106.
Sayar, K, Aksu, G, Ak, I, Tosun, M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;7:1561–1565.
107.Sumpton, JE, Moulin, DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother. 2001;35:557–559.
108.Sindrup, SH, Bach, FW, Madsen, C, Gram, LF, Jensen, TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60:1284–1289.
109.Tasmuth, T, Hartel, B, Kalso, E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6:17–24.
110.Vitton, O, Gendreau, M, Gendreau, J. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(Suppl 1):S27–S35.
111.Detke, MJ, Lu, Y, Goldstein, DJ, Hayes, JR, Demitrack, MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308–315.
112.Brannan, SK, Mallinckrodt, CH, Detke, MJ, Watkin, JG, Tollefson, GD. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res. 2005;39:161–172.
113.Arnold, LM, Lu, Y, Crofford, LJ, et al.A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974–2984.
114.Norregaard, J, Volkmann, H, Danneskiold-Samsoe, B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445–449.
115.Anderberg, UM, Marteinsdottir, I, von Knorring, L. Citalopram in patients with fibromyalgia—a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4:27–35.
116.Arnold, LM, Hess, EV, Hudson, JI, Welge, JA, Berno, SE, Keck, PE Jr.A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191–197.
117.O'Malley, PG, Jackson, JL, Santoro, J, Tomkins, G, Balden, E, Kroenke, K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999;48:980–990.
118.O'Malley, PG, Balden, E, Tomkins, G, Santoro, J, Kroenke, K, Jackson, JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15:659–666.
119.Aragona, M, Bancheri, L, Perinelli, D, et al.Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain. 2005;9:33–38.
120.Wellington, K, Perry, CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs. 2001;15:643–669.
121.Raskin, J, Goldstein, DJ, Mallinckrodt, CH, Ferguson, MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003;64:1237–1244.
122.Rosen, RC, Lane, RM, Menza, M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19:67–85.
123.Keltner, NL, McAfee, KM, Taylor, CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care. 2002;38:111–116.
124.Clayton, AH, Pradko, JF, Croft, HA, et al.Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63:357–366.
125.Deakin, B, Dursun, S. Optimizing antidepressant treatment: efficacy and tolerability. Int Clin Psychopharmacol. 2002;17(Suppl 1):S13–S24.
126.McGahuey, CA, Gelenberg, AJ, Laukes, CA, et al.The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25–40.
127.Black, K, Shea, C, Dursun, S, Kutcher, S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25:255–261.
128.Judge, R, Parry, MG, Quail, D, Jacobson, JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002;17:217–225.
129.Michelson, D, Fava, M, Amsterdam, J, et al.Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363–368.
130.Pinzani, V, Ginies, E, Robert, L, Peyriere, H, Abbar, M, Blayac, JP. Venlafaxine withdrawal syndrome: report of six cases and review of the literature [French]. Rev Med Interne. 2000;21:282–284.
131.Trenque, T, Piednoir, D, Frances, C, et al.Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French Pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2002;11:281–283.
132.Vandel, P, Sechter, D, Weiller, , et al.Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol. 2004;19:585–586.
133.Feighner, JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry. 1995;56:574–579.
134.Thase, ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502–508.
135.Khalifa, M, Daleau, P, Turgeon, J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999;291:280–284.
136.Combes, A, Peytavin, G, Theron, D. Conduction disturbances associated with venlafaxine. Ann Intern Med. 2001;134:166–167.
138.Guelfi, JD, Ansseau, M, Corruble, E, et al.A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol. 1998;13:121–128.
139.Montgomery, SA, Prost, JF, Solles, A, Briley, M. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 1996;11(Suppl 4):47–51.
140.Schatzberg, AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(Suppl 13):30–37.
141.Thase, ME, Tran, PV, Wiltse, C, Pangallo, BA, Mallinckrodt, C, Detke, MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25:132–140.
142.Jick, SS, Dean, AD, Jick, H. Antidepressants and suicide. BMJ. 1995;310:215–218.
143.Barbey, JT, Roose, SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(Suppl 15):42–48.
144.Isbister, GK, Bowe, SJ, Dawson, A, et al.Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277–285.
145.Dams, R, Benijts, TH, Lambert, WE, et al.A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol. 2001;25:147–151.
146.Schweizer, E, Feighner, J, Mandos, LA, et al.Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 1994;55:104–108.
147.Ereshefsky, L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol. 1996;16(Suppl 2):37S–53S.
148.Settle, EC Jr.Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry. 1998;59(Suppl 16):25–30.
149.Mazur, JE, Doty, JD, Krygiel, AS. Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy. 2003;23:1668–1672.
150.Kelly, CA, Dhaun, N, Laing, WJ, et al.Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol. 2004;42:67–71.
151.Buckley, NA, McManus, PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325:1332–1333.
152.Cheeta, S, Schifano, F, Oyefeso, A, et al.Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry. 2004;184:41–47.
153.Medicine and Healthcare Products Regulatory Agency Web site. Available at: http://www.mhra.gov.uk. Accessed on December 13, 2004.
154.Thompson, C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999;60(Suppl 17):18–22
155.Nierenberg, AA, DeCecco, LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5–9.
156.Paykel, ES, Ramana, R, Cooper, Z, et al.Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171–1180.